Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718791 · ClinicalTrials.gov registry record
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
A clinical trial of GVHD,Acute, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05718791 is a study of GVHD,Acute that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05718791, a study of GVHD,Acute, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST blood sample
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2026-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05718791
The ClinicalTrials.gov registry entry for NCT05718791 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GVHD,Acute appearing as the primary indexed condition, and to 1 intervention - of which blood sample is the first listed.
NCT05718791 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05718791 about?
NCT05718791 is a clinical study titled "CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease". The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cel...
What is the current status of trial NCT05718791?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-05-10. Estimated completion is 2026-12-30.
What conditions does trial NCT05718791 study?
This clinical trial studies the following conditions: GVHD,Acute.
What interventions are being tested in trial NCT05718791?
The interventions under investigation include: blood sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05718791?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718791 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GVHD,Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.